Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Curr Microbiol ; 80(9): 285, 2023 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-37452917

RESUMEN

Pigments produced by micro-organisms could contribute to their pathogenesis and resistance. The investigation into the red pigment of R. mucilaginosa and its ability to survive and resist has not yet been explored. This study aimed to investigate the survival and resistance of the R. mucilaginosa CQMU1 strain following inhibition of pigment production by naftifine and its underlying mechanism. The red-pigmented Rhodotorula mucilaginosa CQMU1 yeast was isolated from an infected toenail of a patient with onychomycosis. Cultivation of R. mucilaginosa in liquid and solid medium showed the effect of naftifine after treatment. Then, analysis of phagocytosis and tolerance to heat or chemicals of R. mucilaginosa was used to evaluate the survival and resistance of yeast to different treatments. Naftifine reversibly inhibited the pigmentation of R. mucilaginosa CQMU1 in solid and liquid media. Depigmented R. mucilaginosa CQMU1 showed increased susceptibility toward murine macrophage cells RAW264.7 and reduced resistance toward different types of chemicals, such as 1.5-M NaCl and 0.5% Congo red. Inhibition of pigment production by naftifine affected the survival and growth of R. mucilaginosa and its resistance to heat and certain chemicals. The results obtained could further elucidate the target of new mycosis treatment.


Asunto(s)
Alilamina , Rhodotorula , Humanos , Animales , Ratones , Alilamina/farmacología
2.
Mycopathologia ; 185(2): 373-376, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31760556

RESUMEN

Trichosporon asahii and Rhodotorula mucilaginosa are important fungal species causing disseminated disease in immunocompromised patients. Onychomycosis prevalence rate ranges from 2 to 30%, which were 50% of nail diseases and 30% of superficial mycosis, respectively. Although important, little is known about the co-habitation of T. asahii and R. mucilaginosa in the causation of onychomycosis. Here, we present the co-habitation of T. asahii and R. mucilaginosa as causative agents of onychomycosis in a healthy 41-year-old male in China. Direct microscopic examination, fungal culture and MALDI-TOF MS were employed in isolated pathogens; hence, antifungal susceptibility test was evaluated. T. asahii was sensitive to posaconazole, voriconazole and itraconazole, whereas R. mucilaginosa was sensitive to both 5-flucytosine and amphotericin B. This report highlights the co-habitation of T. asahii and R. mucilaginosa in the causation of onychomycosis and to raise the awareness of this infection among dermatologists.


Asunto(s)
Coinfección , Uñas , Rhodotorula , Trichosporon , Adulto , Antifúngicos/farmacología , Coinfección/tratamiento farmacológico , Coinfección/microbiología , Dermatomicosis/tratamiento farmacológico , Farmacorresistencia Fúngica , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Uñas/microbiología , Uñas/patología , Onicomicosis/tratamiento farmacológico , Onicomicosis/microbiología , Rhodotorula/efectos de los fármacos , Rhodotorula/aislamiento & purificación , Trichosporon/efectos de los fármacos , Trichosporon/aislamiento & purificación , Tricosporonosis/tratamiento farmacológico , Tricosporonosis/microbiología
3.
Front Biosci (Landmark Ed) ; 25(4): 710-721, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31585913

RESUMEN

Adenosine deaminase acting on RNA1 (ADAR1) is an RNA editing enzyme that modulates the replication of several viruses. Here, we provide evidence showing that ADAR1 stimulates hepatitis B virus (HBV) DNA replication in hepatocellular carcinoma cell lines that are transiently or stably-transfected with HBV. We show that overexpression of ADAR1 promotes the replication of all four HBV genotypes (A, B, C, and D). Furthermore, analysis by mutagenesis shows that RNA editing region, and to a lesser content, RNA binding region of ADAR is responsible for the promotion of replication. Together, these data show that ADAR1 stimulates HBV replication.


Asunto(s)
Adenosina Desaminasa/genética , Virus de la Hepatitis B/genética , Proteínas de Unión al ARN/genética , Replicación Viral/genética , Adenosina Desaminasa/metabolismo , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/virología , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica , Células Hep G2 , Virus de la Hepatitis B/fisiología , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/virología , Interferencia de ARN , Proteínas de Unión al ARN/metabolismo
4.
Medicine (Baltimore) ; 98(51): e18442, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31861015

RESUMEN

Genetic variation and genotype of Hepatitis B virus (HBV) are related to the efficiency of interferon alpha (IFN-α)-based antiviral therapy. However, the correlation of variation in interferon-stimulated response element (ISRE) and HBV genotype response to IFN-α therapy remains elusive.Differences of ISRE between genotype B and C HBV were explored using the HBV sequences retrieved from GenBank, and further investigated by ISRE region cloning and sequencing from 60 clinical samples post-IFN-α therapy. Additionally, ISRE mutants were constructed and their relation to responsiveness of IFN-α was evaluated by real-time PCR and Southern blot analysis.ISRE pattern between genotype B and C were found based on both clinical sample sequencing and full-length sequence alignment. The primary difference is the fourth base within the ISRE region, with T and C for genotype B and C, respectively. HBV with genotype C-type ISRE had a higher replicative capability as compared to HBV with genotype B-type ISRE after IFN-α treatment in huh7 cells. CONCLUSION:: Preference of ISRE between genotype B and C HBV are distinct. Single nucleotide difference (C to T) within the HBV ISRE region may link to the efficacy of IFN-α therapy to genotype B and C HBV. Therefore, this study provides a clue for the determination of IFN-α therapy response to HBV treatment.


Asunto(s)
Virus de la Hepatitis B/efectos de los fármacos , Hepatitis B/tratamiento farmacológico , Interferón-alfa/farmacología , Elementos de Respuesta , Adulto , Femenino , Genotipo , Virus de la Hepatitis B/genética , Humanos , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Mutación , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA